Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Эволюция методов иммунотерапии псориаза и псориатического артрита: от тотальной иммуносупрессии к избирательному воздействию на терапевтические мишени

https://doi.org/10.33667/2078-5631-2020-15-15-21

Полный текст:

Аннотация

В литературном обзоре представлены данные о существующих методах лечения псориаза (П) и псориатического артрита (ПсА). Актуальность работы связана с трудностями выбора практическим врачом того или иного терапевтического средства в зависимости от особенностей течения кожного патологического процесса, поражения костно-мышечной системы, позвоночника и сопутствующих заболеваний. Синтетические и таргетные препараты описаны в историческом аспекте, в обзоре представлены накопленные сведения об их эффективности в отношении различных проявлений П и ПсА, рассмотрены вопросы безопасности их применения. В заключение обсуждены существующие рекомендации по дифференцированному применению различных средств на основании комплексной оценки клинической характеристики больных с учетом, в том числе, риска проявления побочных эффектов терапии.

Об авторах

О. А. Притуло
ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»
Россия

Доктор медицинских наук, профессор, заведующий кафедрой дерматовенерологии и косметологии, главный внештатный специалист-дерматовенеролог Минздрава Республики Крым

Симферополь, Республика Крым 



А. А. Петров
ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»
Россия

Ординатор кафедры дерматовенерологии и косметологии

Симферополь, Республика Крым



А. В. Петров
ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»
Россия

Доктор медицинских наук, профессор, профессор кафедры внутренней медицины № 2, главный внештатный специалист-ревматолог Минздрава Республики Крым Медицинская академия имени С.И. Георгиевского

Симферополь, Республика Крым



Список литературы

1. Saurat J.H., Stingl G., Dubertret L., Papp K., Langley R.G., Ortonne J.P., Unnebrink K., Kaul M., Camez A., Investigators C. S. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (champion) // Br. J. Dermatol. 2008; 158: 558–566.

2. Warren R. B., Mrowietz U., von Kiedrowski R., Niesmann J., Wilsmann-Theis D., Ghoreschi K., Zschocke I., Falk T.M., Blodorn-Schlicht N., Reich K. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (metop): A 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial // Lancet. 2017; 389: 528–537.

3. De Vries A.C., Thio H.B., de Kort W.J., Opmeer B.C., van der Stok H. M., de Jong E. M., Horvath B., Busschbach J. J., Nijsten T. E., Spuls P. I. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: The psoriasis infliximab vs. Etanercept comparison evaluation (piece) study // Br. J. Dermatol. 2017; 176: 624–633.

4. Schmitt J., Zhang Z., Wozel G., Meurer M., Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials // Br. J. Dermatol. 2008; 159: 513–526.

5. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase iii trial // Lancet. 2006; 367: 29–35.

6. Leonardi C. L., Powers J. L., Matheson R. T., Goffe B.S., Zitnik R., Wang A., Gottlieb A.B., Etanercept Psoriasis Study Group Etanercept as monotherapy in patients with psoriasis // N. Engl. J. Med. 2003; 349: 2014–2022.

7. Papp K. A., Tyring S., Lahfa M., Prinz J., Griffiths C. E.M., Nakanishi A. M., Zitnik R., van de Kerkhof P.C.M., Grp E.P.S. A global phase iii randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction // Br. J. Dermatol. 2005; 152: 1304–1312.

8. Tyring S., Gordon K. B., Poulin Y., Langley R. G., Gottlieb A.B., Dunn M., Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis // Arch. Dermatol. 2007; 143: 719–726.

9. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study // J Am Acad Dermatol. 2006; 55: 598–606.

10. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008; 58: 106–15.

11. Leonardi C. L., Kimball A. B., Papp K.A., Yeilding N., Guzzo C., Wang Y.H., Li S., Dooley L. T., Gordon K. B., Investigators P. S. Efficacy and safety of ustekinumab, a human interleukin 12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (phoenix 1) // Lancet. 2008; 371: 1665–1674.

12. Papp K. A., Langley R. G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., Guzzo C., Hsu M. C., Wang Y. H., Li S., et al. Efficacy and safety of ustekinumab, a human interleukin 12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (phoenix 2) // Lancet. 2008; 371: 1675–1684.

13. Garashi A., Kato T., Kato M., Song M., Nakagawa H., Grp J.U.S. Efficacy and safety of ustekinumab in japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. J. Dermatol. 2012; 39: 242–252.

14. Tsai T. F., Ho J. C., Song M., Szapary P., Guzzo C., Shen Y.K., Li S., Kim K. J., Kim T.Y., Choi J.H., et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in taiwanese and korean patients (PEARL) // J. Dermatol. Sci. 2011; 63: 154–163.

15. Zhu X., Zheng M., Song M., Shen Y. K., Chan D., Szapary P. O., Wang B., Investigators L. Efficacy and safety of ustekinumab in chinese patients with moderate to severe plaque-type psoriasis: Results from a phase 3 clinical trial (LOTUS) // J. Drugs Dermatol. 2013; 12: 166–174.

16. Griffiths C.E., Strober B.E., van de Kerkhof P., Ho V., Fidelus-Gort R., Yeilding N., Guzzo C., Xia Y., Zhou B., Li S., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis // N. Engl. J. Med. 2010; 362: 118–128.

17. Langley R. G., Elewski B. E., Lebwohl M., Reich K., Griffiths C. E., Papp K., Puig L., Nakagawa H., Spelman L., Sigurgeirsson B., et al. Secukinumab in plaque psoriasis – results of two phase 3 trials // N. Engl. J. Med. 2014; 371: 326–338.

18. Blauvelt A., Prinz J.C., Gottlieb A.B., Kingo K., Sofen H., Ruer-Mulard M., Singh V., Pathan R., Papavassilis C., Cooper S., et al. Secukinumab administration by pre-filled syringe: Efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) // Br.J. Dermatol. 2015; 172: 484–493.

19. Paul C., Lacour J. P., Tedremets L., Kreutzer K., Jazayeri S., Adams S., Guindon C., You R., Papavassilis C., Grp J.S. Efficacy, safety and usability of secukinumab administration by autoinjector/ pen in psoriasis: A randomized, controlled trial (JUNCTURE) // J. Eur. Acad. Dermatol. 2015; 29: 1082–1090.

20. Blauvelt A., Reich K., Tsai T. F., Tyring S., Vanaclocha F., Kingo K., Ziv M., Pinter A., Vender R., Hugot S., et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the clear study // J. Am. Acad. Dermatol. 2017; 76: 60–69.

21. Thaci D., Blauvelt A., Reich K., Tsai T. F., Vanaclocha F., Kingo K., Ziv M., Pinter A., Hugot S., You R.Q., et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: Clear, a randomized controlled trial // J. Am. Acad. Dermatol. 2015; 73: 400–409.

22. U. S. Food and Drug Administartion Fda Approves New Psoriasis Drug Taltz [(accessed on 16 June 2017)].

23. Mease P. J., van der Heijde D., Ritchlin C. T., Okada M., Cuchacovich R. S., Shuler C. L., Lin C. Y., Braun D.K., Lee C.H., Gladman D.D., et al. Ixekizumab, an interleukin 17a specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial spirit-p1 // Ann. Rheum. Dis. 2017; 76: 79–87.

24. Nash P., Kirkham B., Okada M., Rahman P., Combe B., Burmester G. R., Adams D.H., Kerr L., Lee C., Shuler C. L., et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the spirit-p2 phase 3 trial // Lancet. 2017.

25. Griffiths C.E., Reich K., Lebwohl M., van de Kerkhof P., Paul C., Menter A., Cameron G. S., Erickson J., Zhang L., Secrest R. J., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (uncover 2 and uncover 3): Results from two phase 3 randomised trials // Lancet. 2015; 386: 541–551.

26. Mease P. J., Gladman D. D., Ritchlin C. T., Ruderman E. M., Steinfeld S. D., Choy E. H., Sharp J. T., Ory P.A., Perdok R. J., Weinberg M.A., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial // Arthritis Rheumatol. 2005; 52: 3279–3289.

27. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) // Br J Dermatol. 2008; 158: 558–66.

28. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial // J Am Acad Dermatol. 2008; 58: 106–15.

29. Papp K., Reich K., Leonardi C. L., Kircik L., et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (ESTEEM) // J Am Acad Dermatol. 2015 Jul; 73 (1): 37–49.

30. Reich K., Gooderham M., Green L., Bewley A., et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE) // J Eur Acad Dermatol Venereol. 2017 Mar; 31 (3): 507–517.

31. Qu X., Zhang S., Tao L., Song Y. A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE) // Expert Rev Clin Pharmacol. 2016 Jun; 9 (6): 799–805.

32. Zhang JZ, Tsai TF, Lee MG, et al. The effi- cacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a Phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci 2017; 88: 36–45.

33. Asahina A, Etoh T, Igarashi A, et al. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study. J Dermatol 2016; 43: 869–880.

34. Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoria- sis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015; 173: 949–961.

35. Bissonnette R, Iversen L, Sofen H, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol 2015; 172: 1395–1406.

36. Bachelez H, van de Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015; 386: 552–561.

37. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167: 668–677.

38. Coates L. C., Kavanaugh A., Mease P. J., Soriano E.R., Laura Acosta-Felquer M., et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis // Arthritis Rheumatol. 2016 May; 68 (5): 1060–71.


Для цитирования:


Притуло О.А., Петров А.А., Петров А.В. Эволюция методов иммунотерапии псориаза и псориатического артрита: от тотальной иммуносупрессии к избирательному воздействию на терапевтические мишени. Медицинский алфавит. 2020;(15 (2020)):15-21. https://doi.org/10.33667/2078-5631-2020-15-15-21

For citation:


Pritulo O.A., Petrov A.A., Petrov A.V. Evolution of immunotherapy methods for psoriasis and psoriatic arthritis: from total immunosuppression to selective treatment of therapeutic targets. Medical alphabet. 2020;(15 (2020)):15-21. (In Russ.) https://doi.org/10.33667/2078-5631-2020-15-15-21

Просмотров: 21


ISSN 2078-5631 (Print)